Response Biomedical appoints Chinese distributor:
This article was originally published in Clinica
Executive Summary
Shanghai Kehua is to sell Canadian company Response Biomedical's RAMP cardiac marker tests for CK-MB, troponin I and myoglobin in China. Shanghai, the largest diagnostic reagent manufacturer and distributor in China, will also participate in the registration process. Response's RAMP system delivers highly accurate results in less than ten minutes, the company says. The total in vitro diagnostics market in China was estimated at $327 million in 1999 and this is expected to grow at a compound rate of 16.3% annually through 2005, according to Vancouver-based Response.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.